Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
